A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
Trial details
- Registry ID
- NCT06340360
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as LY3471851 (formerly); NKTR-358; REZPEG
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)NCT06340360 | NKTR | Phase 2 | Completed | 2025-11-26Actual |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic DermatitisNCT06136741 | NKTR | Phase 2 | Active not recruiting | 2025-05-06Actual |
| A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisNCT07690371 | NKTR | Phase 3 | Recruiting | 2028-05Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |